Geum.ru

И. М. Сеченова На правах рукописи Шевчук Ирина Мусаевна комплексный подход к лечению больных диссеминированным раком почки 14. 00. 14 онкология диссертация

Вид материалаДиссертация

Содержание


Neidhart JA. Interferon therapy for treatment of renal cancer. // Cancer. 1986; 57: 1696-1699.
Oda H, Machinami R. Sarcomatoid renal cell carcinoma. A study of its proliferative activity. //Cancer 1993; 71: 2292-8.
Подобный материал:
1   2   3   4   5   6   7

Negrier S, Escuider B, Lasset C, et al. The FNCLCC Crecy trial: Interleukin-2 + interferon is the optimal treatment to induce responses in metastatic renal cell carcinoma.// Proc Am Soc Clin Oncol.1996; 15: abstract 248.

  • Négrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338:1272-1278.

  • Negrier S, Caty A, Lesimple T, et al: Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. //J Clin Oncol 2000; 18:4009-4015.

  • Negrier S. Better Survival With Interleukin-2-Based Regimens? Possibly Only in Highly Selected Patients.// Journal of Clinical Oncology. 22: 1174-1176. 2004.

  • Neidhart JA. Interferon therapy for treatment of renal cancer. // Cancer. 1986; 57: 1696-1699.

  • Nenning H, Rassler H, Minh DN. Heterogeneity of DNA distribution pattern in renal tumors. //Anal Cell Pathol. 14: 9-17. 1997

  • Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhi­bition of FRAP/mTOR.// Proc Natl Acad Sci USA 2001; 98: 10314-10319.

  • Oda H, Machinami R. Sarcomatoid renal cell carcinoma. A study of its proliferative activity. //Cancer 1993; 71: 2292-8.

  • Onda H, Yasuda M, Serizawa A, et al. Clinical outcome in localized renal cell carcinomas related to immunoexpression of proliferating cell nuclear antigen, Ki-67 antigen, and tumor size. //Oncol Rep 1999; 6:1039-43.
  • Oremek GM, Sapoutzis N, Kramer W, Bickeboller R, Jonas D. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.//
    Anticancer Res 2000 Nov-Dec;20(6D):5095-8.
  • Palmer PA, Atzpodien J, Philip T, et al: A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. //Cancer Biother 1993; 8:123-136.
  • Pantuck AJ, Zisman A, Belldegrun A. Biology of renal cell carcinoma: changing concepts in classi­fication and staging. //Semin Urol Oncol 2001; 19:72-9.
  • Paolorossi F, Villa S, Barni S, et al. Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy. // Tumori. 1995 Jan-Feb;81(1):45-7.
  • Paul R, Necking U, Ewing C, et al. Cadherin-6: A new prognostic factor in renal cell carcinoma. //European Urology 2002; Vol. 1. N 1: 139.
  • Pfannschmidt J., Hoffman H., Muley T., et al. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma// Ann Thorac Surg., 2002. – Vol. 74. - № 5. – P. 1653 – 1657.
  • Piltz S, Meimarakis G, Wichmann M, et al. Long-term results after pulmonary resection of renal cell carcinoma metastases.// Ann Thorac Surg, 2002. - Vol.73. – Р. 1082 – 1087
  • Pomer S, Klopp M, Steiner HH, Brkovic D, et al. Brain metastases in renal cell carcinoma. Results of treatment and prognosis. // Urologe A. 1997 Mar;36(2):117-25.
  • Porta C., Paglino C., Imarisio I., et al. Gemcitabine (GEM) and oxaliplatin (l-OHP) to treat immunotherapy-resistant advanced renal cell carcinoma (ARCC) patients (pts.): preliminary results of a single institution phase II study.// Eur J of Cancer Suppl. 2003; V.1, N.5: S261
  • Potenzoni M., Benecchi L, Uliano N, et al. A phase II study of chronic low dose of interleukin-2 (IL-2) and -interferon (IFN-) in metastatic renal cell carcinoma (MRCC). // Eur Urol. 2002; 1 (suppl 1): 109
  • Rinehart JJ, Young D, Laforge J, et al. Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: Immunological and biological effects.// Cancer Research. 1987; V-47: 2481-2485.
  • Rini BI, Weinberg V, Small EJ. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.// Cancer. 2005 Feb 1;103(3):553-8.
  • Rioux-Leclercq N, Turlin B, Bansard J, et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma.//Urology 2000; 55:501-5.
  • Rohde D, Brkovic D, Honig, et al. All-trans retinoic acid and interferon-alpha for treatment of human renal cell carcinoma multicellular tumor spheroids. // Urol Int. 2004;73(1):47-53.
  • Roigas J, Deger S, Schroeder J, et al. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma.
    Urol Res. 2003 Dec;31(6):358-62. Epub 2003 Sep 26.
  • Roigas J, Schulze G, Raytarowski S, Jung K, et al. Tumor m2 pyruvate kinase in plasma of patients with urological tumors.//Tumour Biol 2001 Sep-Oct;22(5):282-5.
  • Rosenberg SA. Immunotherapy of cancer using interleukin-2 current status and future prospects. // Immune Today 1988; 9:58
  • ссылка скрыта, ссылка скрыта, ссылка скрыта, et al. Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer.// Ann Oncol. 1995 Dec;6(10):999-1003.
  • Salma S, TrifunovicJ, Nikolin B. Metastatic Renal Cell Carcinoma and Capecitabine - Salvage Therapy after Treatment with Interferon. // Annals of Oncology, 2004; V. 15 (suppl 3): Abstract: 449P
  • Sampaio C, Olencki T, Murthy G, et al. Phase II trial of circadian infusion of the antimetabolite floxuridine in patients with metastatic RCC.// J Inf Chemotherapy; V-4: 100-103, 1994.
  • Sandhu SS, Symes A, A'Hern R, et al. Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma.// BJU Int. 2005 Mar;95(4):522-5.
  • Sandock DS, Seftel AD, Resnick MI: Adrenal metastases from renal cell carcinoma: Role of ipsilateral adrenalectomy and defini­tion of stage. //Urology 49:28-31, 1997
  • Schoenberg A, Kirchner H, Fenner M, et al. Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma. // Eur J Cancer 1993; 29A: 737-740
  • Sheriff M H, Low S H, Miura M, et al. Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as a screening assay.// The J of Urol. April 2003; Vol. 169: 1530–1534.
  • ссылка скрыта, ссылка скрыта, ссылка скрыта, et al. A new synthetic matrix metalloproteinase inhibitor modulates both angiogenesis and urokinase type plasminogen activator activity. // Angiogenesis. 1998;2(4):319-29.
  • Stadler WM, Ratain MJ. Development of target-based antineoplastic agents. //Invest New Drugs 2000;18:7-16.
  • Stief C, Matuschek I, Kiczyk MA. Long-term outcome of cytoreductive surgery for recurrent renal cell carcinoma. //Eur Urol 2002; 1 (suppl 1): 111.
  • Tagliaferri P, Barile C, Caraglia M, et al. Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration.// Am J Clin Oncol. 1998; V-21(1): 48-53.
  • Takamizawa A. Nuclear morphometry and DNA content and grading of RCC. // Jpn J Urol.1988; 79 № 6: 1054-1062
  • Thompson JA, Shulman KL, Benyunes MC, et al: Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. //J Clin Oncol 1992; 10:960-968.
  • Tourani J-M, Pfister C, Berdah J-F, et al: Outpatient treatment with subcutaneous interleukin-2 and interferon-a administration in combination with fluorouracil in patients with metastatic renal cell
    carcinoma: results of a sequential nonrandomized phase II study.// J Clin Oncol 1998; 16:2505-2513.
  • Tourani J-M, Pfister C, Tubiana N. Subcutaneous Interleukin-2 and Interferon Alfa Administration in Patients With Metastatic Renal Cell Carcinoma: Final Results of SCAPP III, a Large, Multicenter, Phase II, Nonrandomized Study With Sequential Analysis Design—The Subcutaneous Administration Propeukin Program Cooperative Group.// J of Clin Oncol. 2003; V. 21 (November): 3987-3994
  • Van der Poel HG, Roukema JA, Horenblas S, et al. Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. // Eur Urol. 1999;35(3):197-203.
  • Van Poppel H, Vandendriessche H, Boel K, et al. Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma. //J Urol 1997; 158: 45-9.
  • Wirth MR Immunotherapy for metastatic renal cell carcinoma.// Urol Clin North Am 1993;20:283.
  • Wittke F, Hoffmann R, Buer J, et al. Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. // Br J Cancer.1999;79(7—8):1182-4.
  • Warner E, Tobe SW, Andrulis IL, et al. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. //Am J Clin Oncol. 1995;18: 251-256.
  • Yagoda A, Abi-Rached B, Petrylak D: Che­motherapy for advanced renal-cell carcinoma:1983-1993. //Semin Oncol 1995; 22:42-60.
  • Yang JC, Haworth L, Steinberg SM, et al. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients
    with metastatic renal cancer. Proc Amer Soc Clin Oncol 21:19a (abstract 15): 2002.
  • Yang JC. Bevacizumab for patients with metastatic renal cancer: an update.// Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6367S-70S.
  • Yasunaga Y, Shin M, Miki T, et al. Prognostic factors of renal cell carcinoma: A multivariate analisis. // J Surg Oncol. 1998; 68: 11-8
  • ссылка скрыта, ссылка скрыта, ссылка скрыта, et al. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. // BJU Int. 2004 May;93(7):1087-93.
  • Zambrano NR, Lubensky I A, Merino MJ, et al. Histopathology and molecular genetics of renal tumors toward unification of a classification system. //J Urol 1999; 162:1246-58.